Blood Thinners Called NOACs May Slow Cognitive Decline in Alzheimer's Patients
A large Swedish study finds Alzheimer's patients on NOAC anticoagulants decline cognitively more slowly than those on warfarin or no treatment.
Summary
A study from Karolinska Institutet tracked 7,308 people diagnosed with both atrial fibrillation and Alzheimer's disease. Researchers compared those taking newer anticoagulants called NOACs, those on the older drug warfarin, and those on no blood thinners. Patients on NOACs showed slower cognitive decline — about 0.2 MMSE points per year better than the other groups. While modest year-to-year, the difference could compound meaningfully over time. NOAC users also had lower risks of death, stroke, blood clots, and fractures. Warfarin reduced some risks too but was linked to higher bleeding risk. The study was observational, so causation cannot be confirmed, but findings suggest NOACs may offer brain-protective benefits beyond stroke prevention in older adults managing both conditions.
Detailed Summary
Atrial fibrillation is one of the most common heart rhythm disorders in older adults, and it frequently co-occurs with Alzheimer's disease. Doctors routinely prescribe anticoagulants to reduce stroke risk in these patients, but until now little was known about whether these drugs also affect the course of cognitive decline after Alzheimer's is diagnosed.
Researchers at Karolinska Institutet analyzed data from SveDem, Sweden's national dementia registry, covering 7,308 people with both atrial fibrillation and Alzheimer's disease. Participants were matched into three groups: those taking NOACs (novel oral anticoagulants), those taking warfarin, and those taking no anticoagulant. Cognitive function was tracked over time using the Mini-Mental State Examination.
The key finding: NOAC users declined at a meaningfully slower rate — approximately 0.2 MMSE points per year better than the warfarin and no-treatment groups. Though modest annually, researchers note this gap could translate into a clinically significant preservation of function over several years. The likely mechanism involves improved cerebral blood flow and reduced small-vessel brain damage, both of which are implicated in Alzheimer's progression.
Beyond cognition, NOAC users also showed lower rates of death, stroke, blood clots, and fractures compared to those on no anticoagulant. Warfarin offered some overlapping benefits for mortality, stroke, and clotting, but was associated with a significantly higher risk of major bleeding events — an important safety distinction for older patients.
The study was published in the European Heart Journal and is observational in design, meaning it cannot prove NOACs directly caused slower decline. Confounding factors — such as differences in overall health between groups — could influence the results. Randomized controlled trials are needed to confirm a causal effect. For now, the findings support discussing NOAC therapy with physicians when both conditions are present.
Key Findings
- NOAC users with Alzheimer's and atrial fibrillation declined ~0.2 MMSE points per year more slowly than warfarin or untreated patients.
- NOACs were associated with lower risks of death, stroke, blood clots, and fractures compared to no anticoagulant treatment.
- Warfarin reduced stroke and mortality risk but carried a significantly higher major bleeding risk than NOACs.
- Improved cerebral blood flow and reduced small-vessel brain damage are proposed mechanisms behind NOACs' cognitive benefit.
- The study is observational; randomized trials are needed before NOACs can be recommended specifically to slow cognitive decline.
Methodology
This is a research summary based on a peer-reviewed observational cohort study published in the European Heart Journal by researchers at Karolinska Institutet. The study drew on SveDem, a validated national Swedish dementia registry, with a sample of 7,308 matched patients. As an observational design, it cannot establish causality.
Study Limitations
The observational design means unmeasured confounders — such as overall health status or medication adherence — could partly explain the results. The cognitive difference of ~0.2 MMSE points per year, while potentially cumulative, is small and may not translate into noticeable functional improvement for individual patients. Randomized controlled trials are required to verify a causal relationship between NOAC use and slowed cognitive decline.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: